Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06429150 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06429150 · ClinicalTrials.gov record · last posted 2026-08-27

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

StatusNot Yet Recruiting
PhasePhase 1/2
Started2026-12-31
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.

Protocol amendment history 3 changes detected by DataLookout

2026-08-28
Trial status changed: Recruiting → Not Yet Recruiting
2026-08-28
Primary completion pushed: 2027-07-11 → 2027-12-31
2026-08-28
Completion pushed: 2027-12-31 → 2028-12-31
Trial Details
NCT Number NCT06429150
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions Multiple Myeloma, Plasmacytoma
Enrollment 20 participants
Start Date 2026-12-31
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-27